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4.1 An overview of breast cancer  
Breast cancer (BC) is a significant global public health issue and the leading cause of death among 
women around the world. In 2012, it alone comprised 25% of all cancer cases and 15% of all cancer 
deaths among females [1], making it the most common female cancer. Female BC incidence rates vary 
in different districts, with 10-fold higher rates in Western Europe and United States than in Africa and 
Asia [2]. The international variations in incidence rates largely originate from differences in 
reproductive and hormonal factors and the availability of early detection services [3]. Although 
mortality rates decline in the historically higher-rate countries, they continue to increase in lower-rate 
countries, possibly due to changes in risk factors, as well as limited access to early detection and 
treatment [4, 5]. Conventional therapeutic options in BC are surgery (local), radiation therapy 
(locoregional), endocrine therapy or other targeted therapies and chemotherapy (systemic), often in 
combination or consecutive. Besides, recent and future therapy regimes are more and more focused on 
individual and personalized treatment options. Herein, a greater understanding of the underlying 
biology of BC has resulted in the development of novel therapeutics such as tyrosine kinase inhibitors 
(TKIs), inhibitors of intracellular signaling pathways, angiogenesis inhibitors, and agents that interfere 
with DNA repair [6, 7]. Of note, BC is a complex and extremely heterogeneous disease, with resistance 
to treatment, recurrences and/or metastases which are still puzzling clinicians in current BC therapy [8, 
9].  
4.2 Subtypes of tumors  
The BC patient’s and tumor’s clinicopathological features determined traditional classification of BC, 
such as tumor size, lymph node involvement, histological grade, patient’s age, estrogen receptors (ER), 
progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2 or ErbB2) status. 
Tailored therapy based on these clinicopathological features, used in routine, may still have 
limitations. Therefore, these clinicopathological features will be completed by combining genomic 
information to estimate recurrence risk (prognostic value) and to predict therapeutic efficacy 
(predictive value) [10]. There has been extensive effort to unravel the molecular drivers of this disease, 
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which has led to the classification of BC into at least five intrinsic subtypes associated with patient 
survival, based on gene expression patterns: luminal A, luminal B, basal-like, Her-2 positive and 
normal breast-like [11-13]. Yet, this classification system has not been incorporated in clinic practice at 
the moment [14], and traditional biological features continue to provide an important guide to 
appropriate therapy for individual patients.  
4.2.1 Biological subtypes of tumors 
Based on tumor expression of the ER, PR and HER2, three broad phenotypes of BC are commonly 
used in clinical practice: ER positive, HER2 positive, and triple negative (TNBC, characterized by lack 
of expression of ER, PR, and HER2) [15]. 
4.2.1.1 ER positive BCs 
The role of estrogen in breast carcinogenesis and cancer progression has been already clearly 
established as early as in 1896 since Beatson’s first clinical observation of the antitumor effect of 
ovariectomy in a BC patient [16]. The effects of estrogen on proliferation are mainly mediated by their 
interaction with the ER. Estrogens drive the proliferation of mammary epithelial cells and therefore 
promote the growth of ER positive BC. Approximately 75% of BCs express nuclear staining of ER and 
55% of PR [17, 18]. PR positivity can be considered as a surrogate for ER positivity due to the 
expression of the PR requiring functioning ER [15]. At the gene expression level, ER positive BC 
mainly composes Luminal A and Luminal B subtypes. ER positive tumors are more likely to be smaller, 
lymph node negative and low grade compared to ER negative tumors [18]. The hormone therapies used 
to treat ER positive BC are designed to antagonize the mitogenic effects of estrogens and include: 
selective ER modulators (SERMs) such as tamoxifen (TAM) that bind to ER and act as antagonists in 
the breast [19]; selective ER down-regulators (SERDs) such as fulvestrant that bind to and target ER 
for degradation in any tissues [20]; and aromatase inhibitors (AIs) that inhibit the activity of aromatase 
(CYP19A1) and consequently suppress the peripheral production of estrogen [21].  
4.2.1.2 HER2 positive BCs 
The epidermal growth factor receptor (EGFR) consists of four closely related receptor tyrosine kinases 
(RTKs): EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her3 (ErbB-3) and Her4 (ErbB-4) [22, 23]. This 
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family of receptors functions primarily through a process of signal transduction [24]: the ligand binding 
to the receptors induces homo- or hetero-dimerization, activates the kinase domain, then activates 
down-stream signaling such as the Ras/MAPK and PI3K/AKT signaling pathways [25]. Aberrant 
signal transduction through the EGFR family of RTKs, is a common feature of many types of solid 
tumors [26]. HER2, a transmembrane protein RTK, eventually hetero-dimerizing with ErbB3 [27] is an 
oncogenic driver of the growth of HER2-positive BC. Either EerB-2 gene amplification or HER2 
protein overexpression was independent of all other prognostic factors in BC [28]. At the gene 
expression level, most HER2 positive BC belong to HER2 enriched subtype whereas not all 
molecularly HER2 positive tumors are HER2 overexpressed and HER2 positive BC can be found in all 
intrinsic subtype [13]. In addition, HER2 positive BC are associated with younger age, high nuclear 
grade, more lymph node involvement and negative hormone receptor status [29, 30]. Approximately 
15–20% of breast carcinomas are HER2-positive (HER2+), and half are ER negative [31, 32] which is 
generally considered to be a poor prognostic marker associated with more aggressive disease and a 
higher risk of metastasis. Nonetheless, the approval of newer HER2-targeted agents, e.g. trastuzumab, 
succeed in the last 10 years in improving the prognosis of these patients [33].  
4.2.1.3 Triple-negative BCs (TNBCs) 
Triple-negative breast cancers (TNBCs) represent 15-20% of all BCs [34], and are defined by a lack of 
ER, PR, and HER2 expression, resulting in limited treatment options. TNBC are more aggressive, 
affect younger women, than ER or HER2 positive BC, and are higher in incidence among patients with 
germline BRCA1 mutations [35, 36], or of African ancestry [37]. At the gene expression level, TNBCs 
overlap with the basal-like subtype, but not synonymous [38]. In addition, TNBC have demonstrated 
both a higher rate of recurrence and a worse clinical outcome compared to the other subtypes of BC, 
presenting larger tumors and more likely to be III grade [39]. Due to the lack of well-defined clinical 
targets, limited treatment options are offered and standard chemotherapy, combined or not with 
radiation therapy, is currently the only treatment option for women with TNBC, and there are no 
available preventive drugs [40]. 
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4.2.2 Molecular subtypes of BCs 
In recent decades, global gene expression profiling (GEP) studies of BC have provided a more 
established molecular classification system and identified distinct clusters or intrinsic subtypes based 
on the quantitative expression of several genes (transcriptome profiles). By using the expression of a 
subset (n = 496) of differentially expressed genes in GEP study, Perou and colleagues were able to 
identify two main clusters appeared to be related to ER expression, which allows to classify BC in 4 
main classifications: luminal (with further differentiation in A and B), basal-like, HER2-positive and 
normal breast-like type [11, 12, 41]. The ER positive cluster was enriched with ER, ER-related genes 
and other genes characteristic of the luminal epithelial cells, herein this class was termed as ‘luminal’. 
The luminal cluster was further stratified into subclasses with at least two distinct subclasses reported 
in following studies: luminal A and luminal B subtypes. Compared with luminal B tumors, luminal A 
tumors express higher levels of ER and GATA3 that regulates luminal epithelial cell differentiation in 
the mammary gland [42], whereas luminal B tumors more often express HER1, HER2, and/or cyclin 
E1. Most studies indicated that luminal B tumors were associated with a worse prognosis than tumors 
of the luminal A class [12, 35]. The other major cluster with ER negative shows three distinct 
subclasses termed ‘HER2 positive’, ‘basal-like’ and ‘normal breast-like’. The HER2 subgroup is 
characterized by overexpression of HER2 and other genes concerning to the HER2 amplicon. The 
basal-like class is dominated by TNBCs, characterized by positive expression of genes typical of 
myoepithelial/basal epithelial cells, such as basal cytokeratin. The normal breast-like class displays a 
triple-negative phenotype but has gene expression similar to patterns found in normal breast tissue 
samples. These so-called “intrinsic BC subtypes” provide the basis of a molecular taxonomy of BC and 
they exhibit special molecular characteristics as well as different prognostic impact [43, 44]. 
As intrinsic subtypes are evolving, rarer subtypes, such as claudin low and molecular apocrine, have 
been identified [45-47]. To date, these subtypes have not been validated for clinical routine use [48].  
4.3 Traditional and emerging biomarkers of BCs 
Biomarkers play an essential role in the management of BC patients. The key point to significantly 
increase the survival of the BC patients is the development of specific biomarkers for prognosis and 
prediction then identify effective targeted therapies. Even though many therapies for BC including 
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chemotherapy, endocrine therapy, and target therapies have made a significant contribution to the 
decrease in BC mortality in the past two decades, resistance to treatment such as anti-estrogen agents is 
a major clinical problem in current BC treatment. For example, about 25% of the patients with ER 
positive tumors receiving 5 years adjuvant tamoxifen therapy develop recurrent disease within 10 years, 
and 30-40% of the patients in advanced stage with ER positive primary tumors do not respond to 
anti-estrogen therapy [49]. To overcome the therapy resistance and recurrence/metastasis process, 
deeper understanding of established biomarkers and further exploration of more specific new 
biomarkers for BC are necessary. A good candidate biomarker for monitoring cancer should be directly 
correlated with molecular mechanisms of carcinogenesis in pre-cancerous tissues, differentially 
expressed in various BC populations and reflect response to drug effect. Once a biomarker has been 
identified, targeted agents may be performed in clinical trials within a specifically enriched patient 
population incorporating the predictive biomarker of clinical benefit. Since 2007, international 
guidelines (e.g., St. Gallen, ASCO) have recommended to additionally use validated protein or gene 
expression tests reflecting the intrinsic tumor characteristics to improve the clinical risk stratification to 
avoid under- or overtreatment based on clinicopathological parameters [50, 51]. Several markers have 
shown evidence of clinical usefulness and have been recommended for use in practice in BC patients 
including some established traditional markers like ER, PR, HER2, novel protein markers like 
urokinase plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1) and some molecular 
markers based on certain multigene assays (e.g. Oncotype DX, PAM50 and MammaPrint) [10]. 
4.3.1 Molecular markers assays 
4.3.1.1 MammaPrint 
MammaPrint ® (70-gene signature by Agendia, the Netherlands) was one of the first described 
mRNA-based multigene tests for predicting outcome in patients with BC [52]. The prognostic impact 
and guide to the administration of adjuvant chemotherapy of MammaPrint for both lymph 
node-negative and lymph node-positive patients (1–3 involved nodes) has been extensively 
recommended [53-56]. 
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4.3.1.2 Oncotype DX 
The Oncotype DX test (Oncotype DX™ Breast Cancer Assay by Genomic Health, USA) which is 
performed on paraffin-embedded and formalin-fixed (FFPE) breast tumor tissue is most advanced and 
widely used in clinical practice. This test analyses the expression of 21 genes (16 tumor-related and 5 
housekeeping) at the mRNA level using a quantitative real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) [57, 58]. Oncotype DX recurrence score (RS) may help determine prognosis and 
aid decision-making with respect to administration of adjuvant chemotherapy in newly diagnosed 
ER-positive but HER2-negative BC patients with lymph node–negative invasive disease. In addition, 
Oncotype DX may be considered for identifying HER2-negative, ER-positive patients with 1–3 
involved lymph nodes for treatment with adjuvant chemotherapy [53]. 
4.3.1.3 PAM50 
Although the first definition of the intrinsic subtypes occurred almost two decades ago, an assay suited 
for diagnostic use was introduced recently: PAM50 (Prosigna™ Breast Cancer Prognostic Gene 
Signature Assay: Nanostring Technologies, USA). The test assigns each sample to the intrinsic subtype 
and predict the risk of relapse for ER positive patients, with the potential to be informative for 
identifying women who can benefit from adjuvant treatment [59, 60] 
Besides three biomarkers mentioned above, there are increasing numbers of molecular markers that are 
already commercially available (e.g. Endopredict®, MapQuant Dx®, Breast Cancer Index and 76 gene 
Rotterdam signatures), or are in pre-clinical development or show promise from the research setting.  
4.3.2 Protein markers assays 
4.3.2.1 IHC4 assay 
Besides ER, PR and HER2, Ki67 is a proliferative marker used to predict tumor growth rate, which has 
been shown to be a prognostic biomarker with predictive ability in the adjuvant context [61, 62]. 
Therefore, a combination of the 4 immunohistochemistry (IHC) based biomarkers (ER, PR, HER2 and 
Ki67) analyses could easily be performed on tumor biopsy tissues using FFPE tumor biopsy specimens, 
with a final algorithm calculating a risk score for distant recurrence, as a predictor of risk of distant 
recurrence in BC [63-66]. 
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4.3.2.2 uPA/PAI-1 assay 
With the ability to promote cancer progression, uPA and its inhibitor, PAI-1 are presently amongst the 
best validated prognostic biomarkers for BC. According to updated the European Group on Tumor 
Markers (EGTM), levels of uPA and PAI-1 protein levels may be combined with established factors 
for assessing prognosis and identifying ER-positive, HER2-negative and lymph node–negative BC 
patients that are unlikely to benefit from adjuvant chemotherapy. However, due to the requirement for 
fresh–frozen tissue by a validated ELISA measurement, uPA or PAI-1 not widely used for clinical 
purposes [10, 53, 67].  
Of note, although massive time and money were invested into the development of new BC biomarkers, 
there are still only three biomarkers (ER/PR/HER2) for all BC patients predicting the benefit from 
corresponding therapies (endocrine therapy and anti-HER2 targeted therapy). In addition to these 
mandatory biomarkers, multianalyte tests, such as uPA/PAI-1, Oncotype DX, MammaPrint, Prosigna, 
may be performed in specific subgroups of BC patients [53]. 
4.3.3 Potential and promising biomarkers 
4.3.3.1 Vitamin D receptor VDR 
Besides classic steroid hormone receptors such as ER and PR, some nuclear receptors like retinoid and 
thyroid hormone receptors, peroxisome proliferator-activated receptors (PPARs) and vitamin D 
receptor (VDR)  as members of the thyroid–retinoid receptor family of ligand-activated transcription 
factors, also exert profound and complex effects in the etiology of BC [68, 69]. VDR, which is found in 
normal breast tissue and in breast tumors [70], interacts with its ligand calcitriol, the active form of 
vitamin D, to modulate the normal mammary epithelial cell genome and subsequent phenotype [71, 72]. 
The human VDR (hVDR) gene is localized in chromosome 12q12-14, and consists of multiple 
promoter regions (A–C) followed by the coding region spanning exons 2 through 9 [73, 74]. Calcitriol, 
the most active vitamin D metabolite, acts similarly to classical steroid hormones: Ligand-bound 
VDR-calcitriol heterodimerizes with its cognate co-receptor retinoid X receptors (RXR), interacting 
with specific nucleotide sequences (hormone response elements) of target genes and functions via both 
genomic and nongenomic pathways to regulate around 60 target genes expression and produce a 
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variety of biological effects [75]. These target genes are involved in diverse molecular pathways, 
thereby resulting in a wide range of calcitriol-mediated anti-cancer actions via autocrine and paracrine 
including anti-proliferation, anti-inflammation, induction of apoptosis, stimulation of differentiation, 
inhibition of invasion, metastasis and angiogenesis on various malignant cells [76-78], including 
mammary cells [76]. Several epidemiologic, mechanistic and experimental data support the concept 
that optimal vitamin D status has a protective effect against development of BC [79-86], and that 
specific distinct signaling pathways can inhibit BC growth on 3 broad phenotypes (ER+/HER2+/TNBC) 
of BC through calcitriol [72]. For ER positive BC, VDR mediated pathways reduce estrogen synthesis 
and down-regulate ER levels, thus attenuating the stimulus of estrogen on BC cells, leading to 
significant inhibition of BC cells proliferation [87-89]. In HER2 positive BC, vitamin D-mediated 
VDR signaling reduced HER2-regulated downstream signaling in both in vitro and in vivo 
HER2-amplified mammary tumors, determined by down-regulation of the phosphorylation of HER2, 
AKT and ERK, and inhibited the expression of cyclin D1 as a downstream molecular target of cell 
proliferation. But the specific mechanism for the signaling suppression is still unknown [90, 91]. 
Recently, separate pre-clinic studies raised the possibility of developing novel VDR-targeted therapies 
for TNBC [92-95].  
We therefore believe that VDR exploration is very relevant to evaluate its potential as a new prognostic 
biomarker and therapeutic target in BC.  
4.3.3.2 Circulating tumor cells (CTCs)—‘liquid biopsy’ 
To perform the therapeutic monitoring, frequent tumor inspect is needed, but it is not always possible 
due to tumor inaccessibility in cancer patients. ‘Liquid biopsy’ appears to be a promising approach to 
overcome this problem, providing the testing of circulating tumor cells (CTC) and/or tumor-specific 
circulating nucleic acids. CTCs circulate in the peripheral blood of patients with solid malignancies and 
are shed from an existing primary tumor or from metastatic lesions into the blood stream [14]. CTCs 
detected in BC patients are significantly associated with a poor outcome in both early and metastatic 
tumors [15–19]. In metastatic patients, several tumor lesions may potentially release CTCs which 
therefore comprehensively reflect tumor and metastasis characteristics. CTCs can be collected via a 
simple venipuncture; this ‘liquid biopsy’ achieves the repeatable and real-time monitoring of tumor cell 
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characteristics. It is a less invasive and cost-effective alternative to tissue biopsies [20], despite the fact 
that technical and conceptual advances are still necessary before this ‘liquid biopsy’ can be routinely 
used for the diagnosis, characterization, monitoring, and treatment optimization of cancer. CTCs are a 
promising marker, providing important predictive and prognostic information in both early and 
metastatic BC. They may help to assess the response to treatment and to detect early disease recurrence 
[21]. At the moment, the CellSearch® system for CTC enumeration is the only accepted standard by 
the Food and Drug Administration (FDA). Only a few studies have investigated HER2 and/or ER 
expression on CTCs, even though, as discussed ealier, HER2 and ER are currently the only validated 
predictive factors used for therapy decision making in BC [22]. In conclusion, the characterization of 
CTCs may be a major tool to support diagnosis, and should be included in clinical trials for the 
evaluation of new targeted therapies [23]. Detection of biomarkers changes in CTCs during treatment 
that resulted in resistance, is the promising way to shift the way of therapy as well as to find new 
therapeutic targets. In order to better predict disease progression and personalize treatment, new 
prognostic and predictive factors are needed. So far, studies on VDR status in CTCs are still lacking. 
Therefore, the evaluation of VDR expression on CTCs in BC patients could potentially help in 
individualizing BC Therapy.  
4.3.3.3  BRCA1—tumor suppressor  
Breast cancer 1 (BRCA1) is a susceptibility gene responsible for hereditary predisposition to BC. Since 
it was first found to encode a DNA repair enzyme involved in BC susceptibility in 1990 [96] and 
subsequently was successfully cloned in 1994 [97], BRCA1 has received a great deal of attention in BC. 
It has been mapped to chromosome 17q21 containing 24 exons, encoding a pleiotropic full-length 
protein of 1863 amino acids in humans [97]. BRCA1 full-length form is the best-defined BRCA1 gene 
products that contains multiple functional domains, including a highly conserved N-terminal RING 
domain, two nuclear localization signals (NLS) located in the exon 11, a serine-glutamine (SQ) cluster 
between amino acids 1280–1524 [98], and tandem C-terminal BRCA1 (BRCT) domains [99-101]. 
BRCA1 is a serine phosphoprotein regulated in a cell cycle-specific manner [102] and hyper 
phosphorylated in response to DNA damage [103-106]. As tumor suppressor, BRCA1 mediates many 
different molecular processes including double strand (DS) DNA breaks repair, transcriptional 
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activation, apoptosis, cell-cycle checkpoint control, and chromosomal remodeling, binds different 
functional proteins (c-myc, E2F, p53, RAD50, cyclins, CDKs, RNA polymerase etc.), and suppresses 
development of BC and ovarian cancers [107-110]. In addition, perhaps the most interesting among 
BRCA1 protein-protein interactions in mammary epithelial cells is the one with the ER [111]. 
Therefore, genomic sequencing of BRCA1 (and BRCA2) in women with a familial history of one or 
more incidences of early onset BC or ovarian cancer provides a powerful tool to detect disease 
predisposition. However, the genomic test is expensive and not be suitable for detection of sporadic 
cancers associated to somatic events. Overall, about 9.3% of female BC patients carry predisposing 
mutations [112]. Germline mutations of BRCA1 and BRCA2 are responsible for about 50% of 
hereditary BC [113, 114]; nevertheless these mutations account for only 3–8% of all BCs. Most BC are 
sporadic and occur in absence of BRCA1 mutations [115, 116]. In sporadic breast tumors, many 
researchers postulated that loss of heterozygosity (LOH) reduces BRCA1 mRNA and protein levels, 
induces incorrect subcellular localization [117-120] and impaired methylation of the BRCA1 promoter 
region [121-123]. These events lead to noticeable loss of BRCA1 function and provide evidence for 
BRCA1 tumor suppressor function in sporadic forms [124]. Then, besides BRCA mutated BC, 
sporadic cancers may exhibit a so-called ‘BRCAness” feature, as they display a BRCA1 mutation 
phenotype without any mutation [125-128]. Nonetheless, BRCAness is generally associated with 
mutations of other genes of the same signaling pathway. Meanwhile, next to its involvement in the 
tumor suppressing process, BRCA1 is also considered a key player in establishing chemotherapy 
sensitivity and could thus be considered as a predictive factor for patient management [65]. In 
preclinical and clinical studies, the role of BRCA1 in response to DNA-damaging agents and other 
types of chemotherapy agents has only partly been elucidated [129, 130], suggesting that BRCA1 could 
be useful as a predictive marker of response to different types of chemotherapy agents [131]. To the 
best of our knowledge, numerous studies have investigated the clinic pathological value of BRCA1 
protein level or of its subcellular localization in clearly defined breast carcinomas, including sporadic 
and BRCA1 mutated tumors. Nonetheless, in spite of the findings concerning BRCA1 expression, the 
clinical value of its subcellular localization is still controversial, mostly attributable to limited 
techniques and approaches [117, 132-150]. Therefore, the use of BRCA1 as a promising biomarker 
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should be examined more completely in prospective clinical trials, not only in BC but also in other 
cancers where BRCA1 seems to play a role in the development of the tumors such as ovarian, prostate, 
and non-small cell lung cancer.   
4.4 Aim of the study 
4.4.1 VDR expression in various BC cell models and status in CTCs from 
metastatic BC patients (Publication 1 and Review) 
VDR expressed in normal breast tissue and breast tumors has been suggested as a new prognostic 
biomarker in BC. Besides, increasing evidence supports the view that the detection of CTCs predicts 
outcome in early and metastatic BC. Consequently, an evaluation of VDR expression in the CTCs of 
BC patients may allow optimization of their treatment. As an attempt to profile and subtype the CTCs 
of metastatic patients, in publication 1, we describe an innovative triple fluorescence technique that we 
developed to simultaneously visualize the presence of cytokeratin (CK), absence of CD45, and 
expression of VDR. We first characterized BC cell models, before validating the preclinical data in 
CTCs from 23 metastatic BC patients. The data could be published in Publication 1 [151]. In parallel, 
we published a Review summarizing the data of the literature demonstrating the involvement of VDR 
signaling pathway in BC [72]. 
4.4.2 BRCA1 expression induced by etoposide in various breast cancer cell 
lines (Publication 2) 
BRCA1, as a tumor suppressor, exerts an effective influence on protecting DNA integrity to suppress 
the development of BC. BRCA1 expression is induced in response to DNA-damaging agents, like 
etoposide. Our study was designed to explore if cytoplasmic vs nuclear (phosphorylated) BRCA1 
protein levels could be considered as a potential predictive marker for response to chemotherapy in 
both sporadic and hereditary BC. To address this issue, in Publication 2, we evaluated BRCA1 status 
using immunofluorescence (IF) in a panel of cultured breast cell lines with specific properties. In 
addition, we used etoposide, as DNA-damaging reagent, to validate its effect on BRCA1 protein 
regulation, and shed light on BRCA1 expression patterns in representative cell line models of the 
different BC types with or without etoposide treatment. The data were published in Publication 2 [152]. 




5.1 Publication 1:  
Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells 
(CTCS) in Breast Cancer: from Cell Models to Metastatic Patients 
The Vitamin D receptor (VDR) expressed in normal breast tissue and breast tumors has been suggested 
as a new prognostic biomarker in breast cancer (BC). Besides, increasing evidence supports the view 
that the detection of circulating tumor cells (CTCs) predicts outcome in early and metastatic BC. So far, 
studies on VDR status in CTCs are still lacking. Consequently, an evaluation of VDR expression in the 
CTCs of BC patients may allow optimization of their treatment. As an attempt to profile and subtype 
the CTCs of metastatic patients, we established an innovative fluorescence technique using nine BC 
cell lines to visualize, define, and compare their individual VDR status. Afterwards, we tested the CTC 
presence and VDR expression in blood samples (cytospins) collected from 23 metastatic BC patients. 
The results demonstrated major differences in the VDR levels among the nine cell lines. CTC analysis 
from patient blood samples was then performed with an individual assessment of VDR expression on 
each isolated tumor cell. We detected CTCs in 46% of the patients and demonstrated heterogeneities of 
the VDR status, aggregation and size with a total of 42 CTCs individually analyzed. However, due to 
the limited number of patients in this study, no correlation between VDR expression and BC subtype 
classification (according to ER/PR/HER2 expression) could be determined, but our data support the 
view that VDR evaluation is a potential new prognostic biomarker to help in the optimization of 
therapy management for BC patients. 
5.2 Publication 2:  
Evaluation of BRCA1 expression by etoposide in various breast cancer cell lines  
Breast cancer 1 (BRCA1), as a tumor suppressor, exerts an effective influence on protecting DNA 
integrity to suppress the development of breast cancer (BC). BRCA1 expression is induced in response 
to DNA-damaging agents, like etoposide. Germline BRCA1 gene mutations are associated with 
development of hereditary BC. However, besides BRCA mutated BCs, some sporadic cancers may also 
exhibit a BRCA-like phenotype, displaying so-called ‘BRCAness”. This common phenotype may 
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respond to similar therapeutic approaches as BRCA-mutated tumors and may thus have important 
implications for the clinical management of these cancers. In order to determine whether and how 
etoposide regulates the protein levels of BRCA1 in breast cancer cells, we exposed a panel of 5 
selected cell lines to etoposide, compared the results to untreated control cells and then stained the cells 
with the specific, reliable and reproducible MS110 antibody directed against phosphorylated Ser1423 
BRCA1. By evaluating cytoplasmic BRCA1 protein levels, we were able to distinguish 3 aggressive 
BC subtypes with BRCAness characteristics. In addition, determination of early and late apoptosis 
helped to complete the analysis of BRCA1 functions in the DNA damage pathway of aggressive BC. In 
conclusion, our study suggested that cytoplasmic BRCA1 protein levels could be considered as a 
potential predictive marker for response to chemotherapy in both sporadic and hereditary BC. Tumors 
with either BRCAness phenotype or germline BRCA1 mutation are both aggressive BCs associated 
with poor prognosis and could both be subjected to targeted therapies against BRCA1 mutated BC in 
future clinical management strategies. 
5.3 Annex Review:  
Influence of Vitamin D Signaling on Hormone Receptor Status and HER2 
Expression in Breast Cancer 
Breast cancer is a significant global public health issue. It is the leading cause of death among women 
around the world, with an incidence increasing annually. In recent years, there has been more and more 
information in the literature regarding a protective role of vitamin D in cancer. Increasingly preclinical 
and clinical studies suggest that vitamin D optimal levels can reduce the risk of breast cancer 
development and regulate cancer-related pathways. In this review, we focus on the importance of 
Vitamin D in breast cancers, discussing especially the influence of Vitamin D signaling on estrogen 
receptor and human epidermal growth factor receptor 2 (HER-2), two major biomarkers of breast 
cancer today. We discuss the possibility of actual and future targeted therapeutic approaches for 
vitamin D signaling in breast cancer. 
 
  




6.1 Veröffentlichung 1: Fluoreszenzanalyse des Vitamin-D-Rezeptor-Status von 
zirkulierenden Tumorzellen (CTCS) bei Brustkrebs: von Zellmodellen zu 
metastasierten Patienten 
Der Vitamin-D-Rezeptor (VDR), der in normalen Brustdrüsengewebe- und Brusttumoren exprimiert 
wird, wurde als neuer prognostischer Biomarker bei Brustkrebs (BC) vorgeschlagen. Außerdem 
unterstützten zunehmende Anzeichen dafür, die Auffassung, dass die Detektion von zirkulierenden 
Tumorzellen (CTCs) das Ergebnis in der frühem und metastatischen BC prognostiziert kann. Bisher 
fehlen Studien zum VDR-Status in zirkulierenden Tumorzellen (CTCs) noch. Folglich kann eine 
Bewertung der VDR-Expression in den CTCs von BC-Patienten eine Optimierung ihrer Behandlung 
ermöglichen. Als Versuch, die CTCs von metastatischen Patienten zu profilieren und zu unterteilen, 
haben wir eine innovative Fluoreszenztechnik etabliert, die neun BC-Zelllinien verwendet, um ihren 
individuellen VDR-Status zu visualisieren, zu definieren und zu vergleichen. Anschließend testeten wir 
die CTC-Präsenz und VDR-Expression in Blutproben (Zytospins), die von 23 metastatischen 
BC-Patienten gesammelt wurden. Die Ergebnisse zeigten große Unterschiede in den VDR-Levels unter 
den neun Zelllinien. Die CTC-Analyse von Patientenblutproben wurde dann mit einer individuellen 
Beurteilung der VDR-Expression auf jeder isolierten Tumorzelle durchgeführt. Wir haben festgestellt 
CTCs in 46% der Patienten und demonstrierte Heterogenität des VDR-Status, Aggregation und Größe 
mit insgesamt 42 CTCs individuell analysiert. Aufgrund der begrenzten Anzahl der Patienten in dieser 
Studie konnte jedoch keine Korrelation zwischen VDR-Expression und BC-Subtyp-Klassifikation 
(gemäß ER / PR / HER2-Expression) festgestellt werden, aber unsere Daten unterstützen die Ansicht, 
dass die VDR-Evaluation eine potenzielle neue vorhersagende Biomarker zur Unterstützung der 
Optimierung des Therapiemanagements für die BC-Patienten ist. 
6.2 Veröffentlichung 2: Bewertung der BRCA1-Expression durch Etoposid in 
verschiedenen Brustkrebszelllinien 
Breast cancer 1 (BRCA1), als Tumorsuppressor, übt einen wirksamen Einfluss auf den Schutz der 
DNA-Integrität aus, infolgedessen die Entwicklung des Brustkrebses (BC) unterdrückt. Die 
BRCA1-Expression wird als Reaktion auf DNA-schädigende Mittel, wie Etoposid, induziert. Germline 
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BRCA1-Gen-Mutationen sind mit der Entwicklung des erblichen BC assoziiert. Allerdings neben den 
BRCA-mutierten BCs können einige sporadische Krebsarten auch einen BRCA-ähnlichen Phänotyp 
zeigen,  der sogenannte "BRCAness" aufweist. Dieser gemeinsame Phänotyp kann auf ähnliche 
therapeutische Ansätze wie BRCA-mutierte Tumore reagieren und somit wichtige Auswirkungen auf 
die klinische Behandlung dieser Krebsarten haben. Um zu bestimmen, ob und wie das Etoposid die 
Proteingehalte von BRCA1 in Brustkrebszellen reguliert, haben wir eine Gruppe von 5 ausgewählten 
Zelllinien gegenüber Etoposid exponiert, die Ergebnisse mit unbehandelten Kontrollzellen verglichen 
und dann die gefärbte Zellen mit dem spezifischen, zuverlässigen und reproduzierbaren 
MS110-Antikörper gegen phosphoryliertes Ser1423 BRCA1 gerichtet hat. Durch die Bewertung der 
zytoplasmatischen BRCA1-Proteinslevel konnten wir 3 aggressive BC-Subtypen mit 
BRCAness-Charakteristiken unterscheiden. Darüber hinaus hat die Bestimmung der frühen und späten 
Apoptose dazu beigetragen, die Analyse der BRCA1-Funktionen im DNA-Schadensweg von 
aggressivem BC abzuschließen. Abschließend stellte unsere Studie vor, dass die zytoplasmatische 
BRCA1-Proteinslevel als potentieller prädiktiver Marker für die Reaktion auf eine Chemotherapie 
sowohl im sporadischen als auch im hereditären BC in Betracht gezogen werden könnten. Tumoren mit 
entweder BRCAness-Phänotyp oder Keimbahn BRCA1-Mutation sind die beide aggressive BCs, die 
mit einer schlechten Prognose assoziiert sind und könnten beider in zukünftigen klinischen 
Management-Strategien einer gezielten Therapie gegen BRCA1 mutierte BC unterzogen werden . 
6.3 Review von Annex: Einfluss der Vitamin-D-Signalisierung auf den 
Hormonrezeptorstatus und die HER2-Expression bei Brustkrebs 
Brustkrebs ist ein bedeutendes globales Thema der öffentlichen Gesundheit. Es ist die führende 
Todesursache bei Frauen auf der ganzen Welt, mit einer jährlich steigenden Inzidenz. In den letzten 
Jahren gab es in der Literatur und Veröffentlichung immer mehr Informationen über eine schützende 
Rolle der Vitamin D bei Krebs. Die Zunehmende präklinische und klinische Studien deuten darauf hin, 
dass das optimale Level der Vitamin D das Risiko für die Brustkrebs-Entwicklung reduzieren und 
Krebs-bezogene Wege regulieren kann. In dieser Review konzentrieren wir uns auf die Bedeutung der 
Vitamin D bei Brustkrebs und diskutieren vor allem den Einfluss der Vitamin-D-Signalisierung auf den 
Östrogenrezeptor und menschlichen epidermalen Wachstumsfaktor Rezeptor 2 (HER-2), die zwei 
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wichtige Biomarker der Brustkrebs heutzutage sind. Wir diskutieren die Möglichkeit von aktuellen und 
zukünftiger zielgerichteten therapeutischer Ansätzen für die Vitamin-D-Signalisierung bei Brustkrebs.  
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7. Publication 1. 
Int. J. Mol. Sci. 2017, 18(6), 1318; doi: 10.3390/ijms18061318 
Fluorescence analysis of vitamin d receptor status of circulating tumor cells (CTCs) in 
breast cancer: From cell models to metastatic patients 
Zhang, X.; Hofmann, S.; Rack, B.; Harbeck, N.; Jeschke, U.; Sixou, S 
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8. Publication 2 
Drugs R D. 2017 Sep 6. doi: 10.1007/s40268-017-0208-6. 
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines 
Zhang, X.; Hofmann, S.; Harbeck, N.; Jeschke, U.; Sixou, S. 
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